Chimeric molecule for the treatment of th2-like cytokine mediated disorders
CA 2469082 A1 · Owner: Hogaboam, Cory M. · Inventors: Kunkel, Steven L.; Jakubzick, Claudia; Hogaboam, Cory M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides uses and methods for alleviating respiratory tract symptoms of allergy, asthma, and of viral bacterial, fungal and parasitic , infections by shifting inappropriate TH2 responses to TH1 responses by administering IL-13 receptor-targeted immunotoxins to the respiratory tract.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 28, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 28, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 28, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.